{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[12,2,12,3],[13,2,13,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910485147503321"]
[null,null,"Titolo",null,"Bipolar disorder : from neuroscience to treatment / / Allan H. Young, Mario F. Juruena, editors"]
[null,null,"Pubbl/distr/stampa",null,"Cham, Switzerland : , : Springer, , [2021]"]
[{"$nulls":4},"©2021"]
[null,null,"ISBN",null,"3-030-72143-4"]
[null,null,"Descrizione fisica",null,"1 online resource (viii, 325 pages)"]
[null,null,"Collana",null,"Current Topics in Behavioral Neurosciences ; ; v.48"]
[null,null,"Disciplina",null,"616.89506"]
[null,null,"Soggetti",null,"Bipolar disorder - Treatment"]
[{"$nulls":4},"Trastorn bipolar"]
[{"$nulls":4},"Terapèutica"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Intro -- Preface -- Contents -- The Neurobiology of Bipolar Disorder -- 1 Introduction -- 2 Neurotransmitters -- 2.1 Serotoninergic System -- 2.2 Dopaminergic System -- 2.3 Norepinephrinergic System -- 2.4 GABAergic System -- 2.5 Glutamatergic System -- 3 Intracellular Signalling -- 4 Adenylate Cyclase Signalling Pathway -- 5 Neurotrophins and Neurogenesis -- 6 Neuroendocrine -- 7 Conclusion -- References -- The Role of Stress in Bipolar Disorder -- 1 Introduction -- 1.1 Activation of Hormonal Systems After Stress -- 1.2 Stress Hormone Receptors -- 2 Stress Hormone Actions on the Brain in Healthy Individuals -- 2.1 Cellular Effects of Stress Hormones on Brain Circuits -- 2.2 Neuronal Circuits and Cognitive Function -- 3 Changes in Stress Responsiveness in Bipolar Disorder -- 3.1 Imbalance in the Stress System: Importance of Genetic and (Early) Life History -- 3.2 Changes in the HPA Axis in Bipolar Disorder Patients -- 4 Changes in Cognitive Function in Bipolar Disorder Related to Stress -- 4.1 Time-Dependent Changes in Cognitive Processing Following Stress in BD Patients -- 4.2 Network Function in BP Patients and Individuals at Risk for Psychopathology -- 5 Concluding Remarks -- References -- The Role of Genetics in Bipolar Disorder -- 1 Introduction: Why Genetics Matters in the Susceptibility to Bipolar Disorder? -- 2 Bipolar Disorder Is Heritable: Twin, Adoption, and Family Studies -- 3 How Many Genes Modulate the Risk of Bipolar Disorder? Linkage Studies, Candidate Gene "]
[{"$nulls":4},"Studies, and Genome-Wide Association S... -- 4 Genetic Overlap Between Bipolar Disorder and Other Brain Disorders: Disorder-Specific or General Genetic Influences? -- 5 The Role of Rare Genetic Variants -- 6 Gene x Environment Studies -- 7 Nongenetic Mechanisms Contributing to the Regulation of Gene Expression: Epigenetics -- 8 Current and Future Lines of Research."]
[{"$nulls":4},"9 Conclusion -- References -- Targeting Mitochondrial Dysfunction for Bipolar Disorder -- 1 The Mitochondria -- 1.1 Mitochondria as an Energy Source -- 1.2 Other Functions of Mitochondria -- 2 Reactive Oxygen Species and Oxidative Stress -- 3 Mitochondria in Bipolar Disorder -- 3.1 Possible Mechanisms of Mitochondrial Dysfunction in Bipolar Disorder -- 3.1.1 A Shift from OXPHOS to Glycolysis -- 3.1.2 Creatine Kinase -- 3.1.3 Calcium -- 3.1.4 Increased Oxidative Stress -- 3.1.5 Neurotransmitters -- 3.1.6 Brain-Derived Neurotrophic Factor (BDNF) -- 3.1.7 NAA -- 3.1.8 Bcl-2 -- 3.2 Mitochondrial Genes -- 4 How Conventional Drugs for Bipolar Disorder Relate to Mitochondrial Functioning -- 5 Mitochondrial Potential Treatments -- 5.1 Likely Beneficial -- 5.1.1 PPAR Agonists -- 5.1.2 Minocycline -- 5.1.3 N-Acetyl-Cysteine (NAC) -- 5.1.4 Co-enzyme Q10 -- 5.1.5 Melatonin -- 5.2 Theoretically Beneficial, but No Studies Have Been Published -- 5.2.1 Ebselen -- 5.2.2 Mangosteen -- 5.2.3 Ketogenic Diet -- 5.2.4 Resveratrol -- 5.2.5 Taurine -- 5.3 Unlikely to Be Beneficial -- 5.3.1 Alpha-Lipoic Acid (ALA) -- 5.3.2 Pyrimidines -- 5.4 Potential Risk of a Manic Switch -- 5.4.1 ALC (Acetyl-L-Carnitine) -- 5.4.2 Creatine Monohydrate (CM) -- 5.4.3 SAMe (S-Adenosyl-Methionine) -- 5.5 Vitamins -- 5.5.1 Vitamin A -- 5.5.2 Vitamin C -- 5.5.3 Vitamin D -- 5.5.4 Vitamin E -- 5.5.5 Vitamins B -- 6 Summary -- References -- Intracellular Signaling Cascades in Bipolar Disorder -- 1 Introduction -- 2 Mitochondrial Dysfunction -- 3 Calcium Channel Modulators -- 4 Intracellular Signaling and Inflammation -- 5 Glycogen Synthase Kinase 3-Beta (GSK3β) -- 6 Protein Kinase C (PKC) and Diacylglycerol (DAG) -- 7 Neurotrophins -- 8 Glutamatergic System -- 9 Dopaminergic System -- 10 Neurohormonal System -- 11 Purinergic System and Mania -- 12 Conclusion -- References."]
[{"$nulls":4},"Sleep and Circadian Rhythm Disorder in Bipolar Affective Disorder -- 1 Bipolar Affective Disorder -- 2 Circadian Rhythm -- 3 Circadian Rhythm and Bipolar Affective Disorder -- 4 Circadian Rhythm Sleep-Wake Disorders -- 4.1 Delayed Sleep Phase Disorder -- 5 Genetics -- 6 Chronotype -- 7 Melatonin and Cortisol -- 8 Social Zeitgeber Theory -- 9 Circadian Rhythm and Bipolar Disorder -- 10 Conclusion -- References -- Neuroendocrine Stress System in Bipolar Disorder -- 1 Introduction -- 2 Endocrine Axis -- 2.1 Regulation of the Hypothalamic-Pituitary-Adrenal Axis -- 2.2 The Glucocorticoid Receptor (GR) -- 2.3 Mineralocorticoid Receptors (MRs) -- 2.4 Molecular Mechanisms for Resistance of Glucocorticoid Receptors -- 3 Abnormalities of the HPA Axis in Depression -- 3.1 Impact of Stress on Bipolar Disorders -- 3.2 Impact of Mediating Factors on the HPA Axis -- 4 Factors Associated with an Endophenotype Increasing Vulnerability -- 5 Conclusion -- References -- Neuroanatomic and Functional Neuroimaging Findings -- 1 Introduction -- 2 Structural Neuroimaging and Diffusion Tensor Imaging Studies -- 2.1 Structural Magnetic Resonance Imaging MRI (sMRI) Findings in BD -- 2.2 Diffusion Tensor Imaging (DTI) Findings in BD -- 2.3 Longitudinal sMRI and DTI Findings -- 3 Functional Neuroimaging -- 3.1 Positron Emission Tomography (PET) -- 3.2 Resting-State Functional MRI (rsfMRI) -- 4 Summary of Main Findings -- 5 Diagnostic Specificity of Neuroimaging Findings -- 5.1 Structural Neuroimaging and DTI Findings -- 5.2 Functional Neuroimaging Findings (PET, rs-fMRI) -- 5.3 Neuroimaging and Pattern "]
[{"$nulls":4},"Classification Methods and the Diagnosis of BD -- 6 Perspectives on the Role of Neuroimaging in the Management of BD Patients -- 6.1 Neuroimaging Studies and Bipolar Disorders Mood States -- 6.2 Neuroimaging Studies, Bipolar Disorders, and Pharmacological Treatment."]
[{"$nulls":4},"6.3 Neuroimaging to Predict Pharmacological Treatment Response -- 6.4 Neuroimaging and Psychotherapy in Bipolar Disorders -- 7 Conclusions -- References -- Structural and Functional Brain Correlates of Neuroprogression in Bipolar Disorder -- 1 Introduction -- 2 Structural Aspects of Neuroprogression in Neuroimaging -- 2.1 Evidence from Cross-Sectional Studies -- 2.1.1 Brain Volume and General Findings -- 2.1.2 Prefrontal Cerebral Cortex -- 2.1.3 Cingulate Cortex -- 2.1.4 Temporal-Limbic Structures -- 2.1.5 Other Brain Structures -- 2.2 Evidence from Longitudinal Studies -- 2.2.1 Brain Volume and General Findings -- 2.2.2 Prefrontal Cerebral Cortex -- 2.2.3 Cingulate Cortex -- 2.2.4 Temporal-Limbic Structures -- 3 Functional Aspects of Neuroprogression in Neuroimaging -- 4 Challenges (Limitations) and Perspectives -- References -- Inflammation as a Mechanism of Bipolar Disorder Neuroprogression -- 1 Introduction -- 2 Evidence of Inflammatory and Infectious Diseases in BD Neuroprogression -- 2.1 Maternal Immune Activation as a Risk Factor for BD Development and Neuroprogression -- 2.2 Role of Infectious Disease as a Trigger to Develop BD Neuroprogression -- 2.3 Autoimmune Disorders and Their Association with BD Neuroprogression -- 2.4 Role of the Gut-Brain Axis on BD Neuroprogression -- 3 Inflammatory and Oxidative Mechanisms in BD Neuroprogression -- 3.1 Mechanisms of Inflammation and Their Contribution to BD Neuroprogression -- 3.2 Oxidative Stress and Mitochondrial Dysfunction Associated with BD Neuroprogression -- 3.3 Peripheral Inflammatory Mediators as a Trigger or Accelerator of BD Neuroprogression -- 3.4 Cerebrospinal Fluid (CSF) System Inflammatory Markers in BD Neuroprogression -- 3.5 Postmortem Inflammatory Markers in BD Neuroprogression -- 4 Conclusions and Future Directions -- References -- Neuropsychology of Bipolar Disorder."]
[{"$nulls":4},"1 Pattern and Magnitude of Impairment -- 2 What Are the Factors that Affect Cognition? -- 2.1 Diagnostic Features -- 2.2 Sleep -- 2.3 Physical Health -- 2.4 Medication -- 3 Summary -- 4 Methods of Assessment -- 4.1 Longitudinal Changes -- 4.2 Identifying Neuropsychological Phenotypic Clusters -- 4.3 Hierarchical Organization of Cognition -- 4.4 Experimental Analysis Methods -- 5 Conclusions -- References -- The Kindling/Sensitization Model and Early Life Stress -- 1 Introduction -- 2 Stress Sensitization -- 3 Stimulant-Induced Behavioral Sensitization -- 4 Episode-Induced Sensitization -- 5 Cross-Sensitization: Neurochemical Commonalities and Inflammatory Mechanisms -- 6 An Epigenetic Basis for Sensitization -- 7 One Genetic and Two Epigenetic Bases for Illness Vulnerability -- 8 More Stress, Episodes, and Substance Abuse in the USA Than Europe Driving Sensitization -- 9 Implications for Treatment -- 10 High Risk Children Deserve Special Attention and Treatment -- 11 Measures Considered for Primary and Secondary Prevention -- 12 Conclusions -- References -- Childhood Maltreatment in Bipolar Disorders -- 1 Introduction -- 2 Childhood Maltreatment and (More Severe) Bipolar Disorders -- 2.1 Childhood Maltreatment as a Risk Factor for Developing Bipolar Disorders -- 2.2 Childhood Maltreatment and the Severity of the Clinical Expression of Bipolar Disorders -- 2.3 Childhood Maltreatment, Psychiatric, and Medical Comorbidities in Bipolar Disorders -- 2.4 Issues About Childhood Maltreatment "]
[{"$nulls":4},"Subtypes, the Timing of Exposure, and Gender -- 3 Moving to Dimensions of Psychopathology in Association with Childhood Maltreatment -- 3.1 Childhood Maltreatment and Dimensions of Psychopathology in Bipolar Disorders -- 3.2 Childhood Maltreatment and Cognition in Bipolar Disorders -- 4 Childhood Maltreatment as Part of a Multiple Hit Model of Susceptibility."]
[{"$nulls":4},"4.1 Interactions Between Childhood Maltreatment and the Genetic Susceptibility to Bipolar Disorders."]